Related Experiment Video

Updated: Aug 18, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Pharmacokinetic and pharmacodynamic interactions of morin and cyclosporin

Shih-Hua Fang1, Yu-Chi Hou, Pei-Dawn Lee Chao

  • 1Department of Microbiology, School of Medicine, China Medical University, Taichung, Taiwan. shfang@mail.cmu.edu.tw

Toxicology and Applied Pharmacology
|May 12, 2005
PubMed

Insights

Morin, a flavonoid, significantly reduced cyclosporine (CsA) levels in mouse tissues. This flavonoid did not alter the CsA-suppressed T helper 1 immune response, suggesting potential for co-administration in immunosuppressive therapy.

Area of Science:

  • Pharmacology
  • Immunology
  • Natural Products

Background:

  • Morin is a flavonoid with reported anti-inflammatory effects.
  • Cyclosporin (CsA) is a critical immunosuppressant for autoimmune diseases and transplant rejection, but has a narrow therapeutic index.
  • Understanding drug interactions is crucial for optimizing CsA therapy.

Purpose of the Study:

  • To investigate the impact of morin on the tissue distribution of CsA in mice.
  • To evaluate the effect of morin on immune cell function, specifically nitric oxide production and T helper 1 cytokine levels, in the presence of CsA.

Main Methods:

  • Mice were orally administered CsA with varying doses of morin daily for two weeks.
  • CsA concentrations in blood, liver, kidney, and spleen were quantified using monoclonal fluorescence polarization immunoassay.
  • Nitric oxide production and T helper 1 cytokine levels were assessed in activated macrophages and spleen, respectively.

Main Results:

  • Morin coadministration dose-dependently decreased CsA concentrations in blood, liver, kidney, and spleen.
  • A dose of 200 mg/kg morin reduced CsA levels by 33% (blood), 17% (liver), 38% (kidney), and 45% (spleen).
  • Morin significantly reduced nitric oxide production by activated macrophages and preserved CsA-suppressed T helper 1 cytokine levels despite reduced spleen CsA concentrations.

Conclusions:

  • Morin coadministration markedly reduces CsA concentrations in lymphoid and non-lymphoid tissues in mice.
  • Morin does not significantly impair the CsA-suppressed T helper 1 immune response.
  • These findings suggest morin may modulate CsA disposition without compromising its immunosuppressive efficacy regarding Th1 responses.

More Related Videos

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Related Concept Videos

Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...